Antibodies News and Research

RSS

GHIT Fund grants US$5.7 million to six global partnerships working on vaccines against malaria

The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, announced today grants of US$5.7 million to six global partnerships working on innovative drugs and vaccines against malaria, tuberculosis and Chagas disease.

8 Nov 2013

Researchers, clinicians discuss recent findings that could bring hope for people with HIV

Since the onset of the AIDS pandemic more than three decades ago, researchers from the lab and physicians in the clinic have been working toward one shared goal: an AIDS-free world. This week, a conference hosted by the journals Cell and The Lancet brought leading researchers and clinicians together to discuss recent findings that could bring hope to the estimated 35 million people world-wide who live with HIV.

7 Nov 2013

New 4th generation HIV assays now available to improve screening for HIV infection

Laboratory Corporation of America Holdings announced today the availability of a 4th generation HIV antigen/antibody combination assay and a new diagnostic algorithm that improves screening for HIV infection.

6 Nov 2013

PDL BioPharma closes financing transaction with Durata Therapeutics

PDL BioPharma, Inc. announced today that it closed a financing transaction with Durata Therapeutics, Inc., a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses.

6 Nov 2013

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates, and Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced an exclusive license agreement for human antibodies directed to an undisclosed target expressed on the surface of various types of cancers.

6 Nov 2013

One Lambda gets CE mark approval in Europe for C1qScreen assay

One Lambda Inc., part of Thermo Fisher Scientific and a leading producer of in vitro diagnostic products for the human leukocyte antigen transplant community, has received CE mark approval in Europe for its C1qScreen assay.

6 Nov 2013

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Biothera announced today top-line results from its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) that evaluated its immunotherapeutic drug candidate, Imprime PGG®, with cetuximab (Erbitux®), carboplatin and paclitaxel compared with the monoclonal antibody and chemotherapy combination alone.

5 Nov 2013

Stem cell therapy after traumatic brain injury promotes lasting cognitive improvement

A stem cell therapy previously shown to reduce inflammation in the critical time window after traumatic brain injury also promotes lasting cognitive improvement, according to preclinical research led by Charles Cox, M.D., at The University of Texas Health Science Center at Houston (UTHealth) Medical School.

4 Nov 2013

Study: Single dose of HPV vaccine may be sufficient to protect cervical cancer

Women vaccinated with one dose of a human papillomavirus (HPV) vaccine had antibodies against the viruses that remained stable in their blood for four years, suggesting that a single dose of vaccine may be sufficient to generate long-term immune responses and protection against new HPV infections, and ultimately cervical cancer, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

4 Nov 2013

Kamada announces new data from Glassia Phase I/II study in pediatric patients with type 1 diabetes

Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, today reported preliminary data from the Company's ongoing extension study of a Phase I/II clinical trial with its lead product Glassia® to treat pediatric patients with a recently diagnosed type 1 diabetes (T1D).

31 Oct 2013

Researchers highlight presence of specific antibodies that regulate appetite in obese patients

Obesity affects more than 15% of adults in France, and its constitutive mechanisms are still not completely explained. Normally, fine control of weight and food intake is coordinated by a specialised part of the brain (the hypothalamus).

31 Oct 2013

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn's leading product under development as a treatment for Human Immunodeficiency Virus (HIV) infection.

31 Oct 2013

Researchers overcome obstacle to using viruses to deliver therapeutic genes

Scientists in The Research Institute at Nationwide Children's Hospital have found a way to overcome one of the biggest obstacles to using viruses to deliver therapeutic genes: how to keep the immune system from neutralizing the virus before it can deliver its genetic payload. In a study published recently in Molecular Therapy, researchers found that giving subjects a treatment to temporarily rid the body of antibodies provides the virus safe passage to targeted cells, allowing it to release a corrective or replacement gene to treat disease.

30 Oct 2013

New DNA vaccine effective against plaques in mouse model of Alzheimer's disease

Amyloid-beta (Aβ) active immunization in Alzheimer's disease can increase the rate of Aβ clearance, and delay cognitive dysfunction, but it is easy to induce meningoencephalitis, which may be related to activation of Th1 lymphocytes.

30 Oct 2013

Researchers complete first phase of landmark study on fungal complications of TB

The first phase of a landmark study of complications of tuberculosis - the first ever carried out in Africa - has been completed by researchers at Wythenshawe Hospital and the University of Manchester working with colleagues in Uganda.

30 Oct 2013

Blood levels of microRNAs may serve as diagnostic tool for thyroid cancer, but more research needed

A new analysis has found that the presence of short segments of genetic material (known as microRNA) within papillary thyroid cancer tumors suggests a likelihood of recurrence after patients undergo surgery.

29 Oct 2013

Children born to mothers with lupus have twice the risk of autism spectrum disorders

According to research presented this week at the American College of Rheumatology Annual Meeting in San Diego, children born to mothers with lupus may be at twice the risk of autism spectrum disorders than those born to mothers without the disease.

28 Oct 2013

Autoimmune link to schizophrenia

Patients with schizophrenia have an increased risk for developing autoimmune diseases, especially if they contract an infection, shows a registry-based study.

24 Oct 2013

Specific antibody patterns predict schizophrenia risk

The presence of antibodies to multiple foods and infectious agents is a risk marker for new-onset schizophrenia, a case-control study suggests.

23 Oct 2013

Tissue-engineered transplants safe and effective in the long term: Study

New results published in The Lancet today [Wednesday 23 October] reveal that five years after the first successful transplantation of a tissue-engineered airway (reported in The Lancet in 2008) the recipient continues to enjoy a good quality of life, and has not experienced any immunological complications or rejection of the implanted airway.

23 Oct 2013

Antibodies News and Research

GHIT Fund grants US$5.7 million to six global partnerships working on vaccines against malaria

Researchers, clinicians discuss recent findings that could bring hope for people with HIV

New 4th generation HIV assays now available to improve screening for HIV infection

PDL BioPharma closes financing transaction with Durata Therapeutics

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

One Lambda gets CE mark approval in Europe for C1qScreen assay

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Stem cell therapy after traumatic brain injury promotes lasting cognitive improvement

Study: Single dose of HPV vaccine may be sufficient to protect cervical cancer

Kamada announces new data from Glassia Phase I/II study in pediatric patients with type 1 diabetes

Researchers highlight presence of specific antibodies that regulate appetite in obese patients

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

Researchers overcome obstacle to using viruses to deliver therapeutic genes

New DNA vaccine effective against plaques in mouse model of Alzheimer's disease

Researchers complete first phase of landmark study on fungal complications of TB

Blood levels of microRNAs may serve as diagnostic tool for thyroid cancer, but more research needed

Children born to mothers with lupus have twice the risk of autism spectrum disorders

Autoimmune link to schizophrenia

Specific antibody patterns predict schizophrenia risk

Tissue-engineered transplants safe and effective in the long term: Study

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo